Updated
Novavax’s Covid vaccine can be administered in the EU. This is a protein vaccine, also known as a dead vaccine.
It is assumed that unvaccinated people who are critical of mRNA vaccines can now also be vaccinated against the coronavirus.
REUTERS
The vaccine NVX-CoV2373 is the first dead vaccine against Covid-19 to be approved.
REUTERS
The Novavax vaccine is the first time a dead vaccine against Covid-19 is approved in the EU.
Studies confirm that the vaccine has an infection protection rate of 90 percent.
The preparation could be an alternative for vaccine skeptics, as it is based on a different technology than the vaccines approved to date.
The EU Medicines Agency (EMA) has cleared the way for the approval of the corona vaccine from the US manufacturer Novavax. The EMA announced on Monday in Amsterdam. After approval by the EU Commission, this will be the fifth corona vaccine in the EU. The responsible commission of experts issued the recommendation after an extraordinary meeting. The experts had already evaluated studies on the effects and risks in the long-running test procedure.
After a detailed assessment, the responsible committee came to the conclusion that “the EU criteria for effectiveness, safety and quality are met,” said the EMA. Now the EU Commission has to give its approval. But that is a matter of form.
Infection protection of 90 percent
The Novavax vaccine (Nuvaxovid) is given in two doses about three weeks apart. According to the studies, it is highly effective with an infection protection of around 90 percent. How strong it works with the very contagious Omicron variant, however, is unclear. So far there have only been cases of mild side effects.
The preparation could be an alternative for vaccination skeptics because it is based on a different technology. Unvaccinated people who have doubts about the rest of the vaccines could potentially be changed their minds. According to a Forsa survey, 56 percent of the unvaccinated in Germany are said to be ready to have a new vaccine injected, as reported by “Focus”.
The Novavax preparation is neither an mRNA vaccine like the preparations from Biontech and Moderna, nor a vector vaccine like those from AstraZeneca and Johnson & Johnson. It contains tiny particles made up of a laboratory-made version of the Sars-CoV-2 spike protein. They are supposed to ensure that the body itself stimulates the production of antibodies and T cells against the virus.
As a member, you become part of the 20-minute community and benefit from great benefits and exclusive competitions every day!
(AFP / job)